---
title: "Cassava Sciences 任命 Dawn C. Bir 加入董事會"
description: "Cassava Sciences Inc. 已任命 Dawn C. Bir 為其董事會成員。Bir 在 Reata Pharmaceuticals、Geron Corporation 和 Soleno Therapeutics 擔任領導職務，擁有豐富的經驗。該公司計劃在 2026 年上半年啓動其針對 TSC 相關癲癇的 simufilam 首個臨牀研究"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/262236431.md"
published_at: "2025-10-22T12:00:32.000Z"
---

# Cassava Sciences 任命 Dawn C. Bir 加入董事會

> Cassava Sciences Inc. 已任命 Dawn C. Bir 為其董事會成員。Bir 在 Reata Pharmaceuticals、Geron Corporation 和 Soleno Therapeutics 擔任領導職務，擁有豐富的經驗。該公司計劃在 2026 年上半年啓動其針對 TSC 相關癲癇的 simufilam 首個臨牀研究

Cassava Sciences Inc. 任命 Dawn C. Bir 為其董事會成員。Bir 擁有來自 Reata Pharmaceuticals、Geron Corporation 和 Soleno Therapeutics 等公司的豐富領導經驗。該公司正在準備於 2026 年上半年開始其針對 TSC 相關癲癇的 simufilam 首個臨牀研究。免責聲明：本新聞簡報由公共技術公司（PUBT）使用生成性人工智能創建。雖然 PUBT 努力提供準確和及時的信息，但此 AI 生成的內容僅供參考，不應被解讀為財務、投資或法律建議。Cassava Sciences Inc. 於 2025 年 10 月 22 日通過 GlobeNewswire 發佈了用於生成本新聞簡報的原始內容（參考 ID：GNW9549844-en），並對此信息的內容承擔全部責任。© 版權 2025 - 公共技術公司（PUBT）

### Related Stocks

- [SAVA.US - Cassava Sciences](https://longbridge.com/zh-HK/quote/SAVA.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Cassava Sciences Faces FDA Request for More Data on Simufilam Epilepsy Trial | Cassava Sciences Inc. has submitted an IND application to the FDA for a simufilam epilepsy trial. The FDA requested more | [Link](https://longbridge.com/zh-HK/news/268413811.md) |
| FDA Puts Cassava's Simufilam Epilepsy Trial On Full Clinical Hold | Cassava Sciences confirmed that the FDA has placed a full clinical hold on its simufilam epilepsy trial, requiring addit | [Link](https://longbridge.com/zh-HK/news/270334808.md) |
| De-Risked Neurology Pipeline and Pivotal 2026 Catalysts Underpin Buy Rating on BMB-101 Franchise | TD Cowen analyst Joseph Thome has maintained a Buy rating on DRUG stock, citing strong clinical performance of BMB-101 i | [Link](https://longbridge.com/zh-HK/news/275923532.md) |
| Stoke Therapeutics spotlights durable Dravet gains, Phase 3 timeline, and new ADOA program at summit | Stoke Therapeutics (NASDAQ: STOK) presented at the Guggenheim Emerging Outlook Biotech Summit 2026, highlighting long-te | [Link](https://longbridge.com/zh-HK/news/276008727.md) |
| Praxis Precision Medicines Eyes Mid-February Dual NDA Filings, Maps ET Launch and Epilepsy Pipeline | Praxis Precision Medicines (NASDAQ: PRAX) executives discussed their regulatory plans and commercial strategies for thei | [Link](https://longbridge.com/zh-HK/news/275990084.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。